Instituto Rosenbusch S.A. (ROSE) - Net Assets

Latest as of December 2025: AR$-526.19 Million ARS ≈ $-380.75K USD

Based on the latest financial reports, Instituto Rosenbusch S.A. (ROSE) has net assets worth AR$-526.19 Million ARS (≈ $-380.75K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AR$7.75 Billion ≈ $5.60 Million USD) and total liabilities (AR$8.27 Billion ≈ $5.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Instituto Rosenbusch S.A. (ROSE) cash flow conversion to assess how effectively this company generates cash.

Key Net Assets Metrics

Metric Value
Current Net Assets AR$-526.19 Million
% of Total Assets -6.79%
Annual Growth Rate N/A
5-Year Change -364.17%
10-Year Change -732.17%
Growth Volatility 203.92

Instituto Rosenbusch S.A. - Net Assets Trend (2000–2025)

This chart illustrates how Instituto Rosenbusch S.A.'s net assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Instituto Rosenbusch S.A. to see how much of total assets are deployed in long-term investments.

Annual Net Assets for Instituto Rosenbusch S.A. (2000–2025)

The table below shows the annual net assets of Instituto Rosenbusch S.A. from 2000 to 2025. For live valuation and market cap data, see ROSE stock market capitalisation.

Year Net Assets Change
2025-12-31 AR$-526.19 Million
≈ $-380.75K
-113.19%
2024-12-31 AR$3.99 Billion
≈ $2.89 Million
-12.26%
2023-12-31 AR$4.55 Billion
≈ $3.29 Million
+1035.45%
2022-12-31 AR$400.51 Million
≈ $289.81K
+101.07%
2021-12-31 AR$199.19 Million
≈ $144.13K
+34.87%
2020-12-31 AR$147.69 Million
≈ $106.87K
+27.86%
2019-12-31 AR$115.52 Million
≈ $83.59K
-20.85%
2018-12-31 AR$145.95 Million
≈ $105.61K
+68.58%
2017-12-31 AR$86.58 Million
≈ $62.65K
+4.01%
2016-12-31 AR$83.24 Million
≈ $60.23K
+17.86%
2015-12-31 AR$70.62 Million
≈ $51.10K
+3.48%
2014-12-31 AR$68.24 Million
≈ $49.38K
+18.37%
2013-12-31 AR$57.65 Million
≈ $41.72K
-12.49%
2012-12-31 AR$65.88 Million
≈ $47.67K
+17.13%
2011-12-31 AR$56.25 Million
≈ $40.70K
+12.05%
2010-12-31 AR$50.20 Million
≈ $36.32K
+6.93%
2009-12-31 AR$46.95 Million
≈ $33.97K
+2.85%
2008-12-31 AR$45.65 Million
≈ $33.03K
+21.73%
2007-12-31 AR$37.50 Million
≈ $27.13K
+4.25%
2006-12-31 AR$35.97 Million
≈ $26.03K
+5.37%
2005-12-31 AR$34.13 Million
≈ $24.70K
+12.26%
2004-12-31 AR$30.41 Million
≈ $22.00K
+7.58%
2003-12-31 AR$28.27 Million
≈ $20.45K
+16.96%
2002-12-31 AR$24.17 Million
≈ $17.49K
+91.96%
2001-12-31 AR$12.59 Million
≈ $9.11K
+5.80%
2000-12-31 AR$11.90 Million
≈ $8.61K
--

Equity Component Analysis

This analysis shows how different components contribute to Instituto Rosenbusch S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 297534.7% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components AR$8.09 Billion %
Total Equity AR$-800.17 Million 100.00%

Instituto Rosenbusch S.A. Competitors by Market Cap

The table below lists competitors of Instituto Rosenbusch S.A. ranked by their market capitalization.

Company Market Cap
Mantle Minerals Ltd
AU:MTL
$5.12 Million
TIMES CHINA HLDGS HD -10
F:T2H
$5.12 Million
Mint Corp
V:MIT
$5.12 Million
Maple Peak Investments Inc
V:MAP
$5.12 Million
China Natural Resources Inc
NASDAQ:CHNR
$5.11 Million
Golden Goliath Resources Ltd.
V:GNG
$5.11 Million
Manchester and London Investment Trust plc
LSE:MNL
$5.11 Million
PMPG Polskie Media S.A.
WAR:PGM
$5.11 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Instituto Rosenbusch S.A.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,739,171,982 to -800,168,048, a change of -4,539,340,030 (-121.4%).
  • Net loss of 4,597,736,040 reduced equity.
  • Other factors increased equity by 58,396,010.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AR$-4.60 Billion -574.6%
Other Changes AR$58.40 Million +7.3%
Total Change AR$- -121.40%

Book Value vs Market Value Analysis

This analysis compares Instituto Rosenbusch S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 AR$1.81 AR$166.00 x
2018-12-31 AR$3.00 AR$166.00 x
2019-12-31 AR$2.46 AR$166.00 x
2020-12-31 AR$3.06 AR$166.00 x
2021-12-31 AR$4.16 AR$166.00 x
2022-12-31 AR$8.52 AR$166.00 x
2023-12-31 AR$97.89 AR$166.00 x
2024-12-31 AR$87.80 AR$166.00 x
2025-12-31 AR$-18.79 AR$166.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Instituto Rosenbusch S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -71.80%
  • • Asset Turnover: 0.83x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-0.45%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 8.43% 12.27% 0.56x 1.24x AR$-186.90K
2001 4.87% 6.96% 0.57x 1.22x AR$-645.90K
2003 12.52% 11.66% 0.85x 1.26x AR$713.50K
2004 8.30% 5.79% 1.11x 1.29x AR$-516.80K
2005 12.18% 7.66% 1.19x 1.33x AR$743.50K
2006 11.40% 6.12% 1.38x 1.35x AR$503.20K
2007 4.80% 2.36% 1.40x 1.45x AR$-1.93 Million
2009 2.13% 1.67% 0.91x 1.40x AR$-3.62 Million
2010 6.02% 5.19% 0.77x 1.50x AR$-1.95 Million
2011 10.56% 8.00% 0.83x 1.60x AR$306.90K
2012 14.54% 11.20% 0.72x 1.80x AR$2.90 Million
2014 13.04% 7.75% 0.76x 2.20x AR$1.94 Million
2015 -1.13% -0.54% 0.82x 2.57x AR$-7.19 Million
2016 13.42% 6.07% 0.85x 2.61x AR$2.59 Million
2017 -0.09% -0.04% 0.81x 2.77x AR$-7.78 Million
2018 0.62% 0.27% 0.82x 2.87x AR$-11.97 Million
2019 -85.11% -21.66% 0.83x 4.74x AR$-99.69 Million
2020 -13.07% -3.04% 0.83x 5.19x AR$-30.02 Million
2021 -11.06% -2.50% 1.05x 4.22x AR$-37.27 Million
2022 -2.23% -0.59% 1.02x 3.72x AR$-44.38 Million
2023 29.40% 12.43% 0.90x 2.63x AR$808.98 Million
2024 -49.86% -17.13% 1.10x 2.65x AR$-2.24 Billion
2025 0.00% -71.80% 0.83x 0.00x AR$-4.52 Billion

Industry Comparison

This section compares Instituto Rosenbusch S.A.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $3,380,505,644
  • Average return on equity (ROE) among peers: 14.38%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Instituto Rosenbusch S.A. (ROSE) AR$-526.19 Million 8.43% N/A $5.12 Million
Laboratorios Richmond SACIF (RICH) $3.38 Billion 14.38% 1.41x $78.78 Million

About Instituto Rosenbusch S.A.

BA:ROSE Argentina Drug Manufacturers - Specialty & Generic
Market Cap
$5.12 Million
AR$7.07 Billion ARS
Market Cap Rank
#28477 Global
#77 in Argentina
Share Price
AR$166.00
Change (1 day)
-0.90%
52-Week Range
AR$118.25 - AR$380.00
All Time High
AR$380.00
About

Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious kera… Read more